| Literature DB >> 31382514 |
Natalia Moratalla-López1, María José Bagur1, Cándida Lorenzo1, M E Martínez-NavarroM Rosario Salinas1, Gonzalo L Alonso2.
Abstract
Crocus sativus L. has been cultivated throughout history to obtain its flowers, whose dried stigmas give rise to the spice known as saffron. Crocetin esters, picrocrocin, and safranal are the main metabolites of this spice, which possess a great bioactivity, although the mechanisms of action and its bioavailability are still to be solved. The rest of the flower is composed by style, tepals, and stamens that have other compounds, such as kaempferol and delphinidin, which have an important antioxidant capacity, and these can be applied in foods, phytopharmaceuticals, and cosmetics. The aim of this work was to provide an updated and critical review of the research on the main compounds of Crocus sativus L. flower, including the adequate analytical methods for their identification and quantification, with a focus on their bioactivity and bioavailability.Entities:
Keywords: anthocyanins; crocetin esters; kaempferols; picrocrocin; safranal
Year: 2019 PMID: 31382514 PMCID: PMC6696252 DOI: 10.3390/molecules24152827
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Plant of Crocus sativus L.
Figure 2Structure and simplified name of the crocins (glycosidic esters of crocetin) found in saffron [6].
Figure 3Structures of picrocrocin and safranal found in saffron [6].
Analytical techniques for saffron analysis.
| Analytical Technique [Reference] | Indicative Data or Analyte | Information |
|---|---|---|
| Spectrophotometry UV-vis [ | Coloring strength, | ISO 3632:2011 |
| HPLC–DAD [ | Crocins, picrocrocin, and safranal | Saffron quality |
| LC/DAD/MS/MS [ | Crocins, picrocrocin, and flavonoids | Identification of saffron metabolites |
| UHPLC–MS/MS [ | Crocins | Differentiation of the obtaining process of saffron |
| NMR [ | Saffron compounds | Metabolic fingerprinting |
| DHS–GC–MS [ | Safranal and other volatile compounds | Quality of aroma |
| e-Nose [ | Volatiles of saffron as a whole | Determination geographical origin |
| PTR–TOFMS [ | Volatile compounds | Quality of aroma |
| Raman spectroscopy [ | Sum of crocins and coloring strength | Saffron quality |
| NIR spectroscopy [ | Control of saffron quality | Saffron Quality/Geographical origin |
| Derivatization–HPLC–DAD [ | Free amino acids and ammonium | Determination of geographical origin |
| MIR spectroscopy [ | FT-IR spectra saffron filaments | Determination of geographical origin |
| Tristimulus colorimetry [ | Color | Saffron quality |
Figure 4Structures of kaempferol 3-O-β-sophoroside 7-O-β-glucoside (1) and kaempferol 3-O-β-sophoroside (2) found in Crocus sativus L. [1].
Figure 5Structure of delphinidin 3,5-di-O-β-glucoside found in Crocus sativus L.
Summary of the main bioactivity of saffron and its bioactive molecules.
| Bioactive Compound | Bioactivity [Reference] | Model | Dose |
|---|---|---|---|
| Cross the blood–brain barrier and reach the central nervous system [ | Rats | Oral administration (100 mg/kg) | |
| Crocetin | Neuroprotection [ | Hemi-Parkinson rats | Peripheral administration (25, 50 and 75 µg/kg body weight) |
| Improved post-shock survival and reduced apoptosis [ | Rats | Bolus injection (2 mg/kg body weight) | |
| Cardioprotective effects (after myocardial ischemia reperfusion injury) [ | Adult male Wistar rats | Intragastric administration (50 mg/kg/day) | |
| Crocins | Hepatoprotective effects [ | Rats | Intraperitoneally (25 mg/ kg body weight/day for 4 weeks) |
| Safranal | Antidepressant [ | Rats | Peripheral administration (15.5 mg/kg body weight.) |
| Anticonvulsant [ | Mice | Injected (0.15 and 0.35 mg/kg) | |
| Picrocrocin | Antitumor effects [ | Human colon adenocarcinoma (Caco-2-cell model) | 8–24 µM |
| Saffron extracts | Satiating [ | Human (randomized, double-blind, placebo-controlled, parallel-group) | Oral administration (capsule: 176.5 mg extract/day for 8 weeks) |
| Reduce cognitive deterioration (Alzheimer’s disease) [ | Patients (randomized double-blind parallel-group) | Oral administration (capsule: 30 mg/day for 12 months) | |
| Saffron | Premenstrual syndrome [ | Women (double-blind, randomized and placebo-controlled trial) | Oral administration (capsule: 30 mg/day for 6 months) |
| Neuroprotection (macular degeneration) [ | Albino rats with light-induced photoreceptors degenerations | Oral administration (1 mg/kg/day for 6 weeks) | |
| Improve the symptoms of children with deficit hyperactivity disorder [ | Children | Oral administration (20–30 mg/ day for 6 weeks) | |
| Effective treatment in depression and anxiety [ | Patients (double-blind controlled clinical trial) | Oral administration (30 mg/day per 6 weeks) |
Summary of the main bioactivity of phenolic compounds of saffron and floral bioresidues of Crocus sativus L. flower.
| Bioactive Compound | Bioactivity [Reference] | Model | Dose |
|---|---|---|---|
| Tepal (ethanol; 80%) extracts of | Hepatoprotective effects [ | Rats | Administration by oral gavage (20 mg/kg body weight for 6 days) |
| Ameliorative effects on kidney failures [ | Rats | Intraperitoneal injection (40 mg/kg body weight for 7/13 days) | |
| Increase antibody response [ | Rats | Intraperitoneal injection (75 mg/kg body weight for 14 days) | |
| Kaempferol aglycone | Antitumor effects [ | Colon cancer cells | 75 µM |
| Anti-inflammatory effects in acute lung injury [ | Cell | 100 µM | |
| Mice | Intraperitoneal injection (50 mg/kg body weight) | ||
| Anti-inflammatory effects [ | Cellular model of intestinal inflammation in rats | 12.5, 25 and 50 µM | |
| Anti-inflammatory effects on | Gastric adenocarcinoma cell | 6.25, 12.5, and 25 µM | |
| Antidepressant effects [ | Chronic social defeat stress mouse model | Intraperitoneal injection (20 mg/kg body weight) | |
| Wound healing effects [ | Incisional and excisional wound models on diabetic and nondiabetic rats | Topically applied (1% weight/weight for 14 days) | |
| Kaempferol 3- | Anti-inflammatory effects [ | Human endothelial cells | >0.05 µM |
| Analgesic effects [ | Mice | Intraperitoneal injection (50 mg/kg body weight) | |
| Quercetin | Chemopreventive effects. Inhibit cell growth and invasion/migration of the cells [ | Cultured oral squamous cell carcinoma cells | 2 mg/mL |
| Chemopreventive effects [ | Male Sprague Dawley rats | Oral administration (200 mg/kg body weigh/ trice a week for 16 weeks) | |
| Delphinidin 3- | Prevent tumor progress by inhibiting angiogenesis and cell migration [ | Breast cancer cells | 200 µM |